News

Team

Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors
Kytopen
January 09, 2023
Events

Kytopen to exhibit at BPI's Biotech Week Boston

Please visit us at Booth 300 at the Cell & Gene Therapy Manufacturing & Commercialization part of...
Kytopen
September 21, 2022
Events

Kytopen to exhibit at Advanced Therapies Week in Miami Jan. 25th – 28th.

Please visit us at Booth 635 to see a demonstration of our Flowfect® Tx for cGMP-compliant cell...
Kytopen
January 14, 2022
Partners

On a Journey to Drastically Speed Up Cell Therapy Manufacturing, Kytopen Lands $30M Series A

Spun out of an MIT lab, sitting in an office space above a Cambridge tapas restaurant from...
Kytopen
October 04, 2021
Partners

MIT Cell-Engineering Spinout Nets $30M for Mass Manufacturing Platform

One of the tricks of getting cell therapies to work is getting the payload you want into the cell...
Kytopen
September 29, 2021
Partners

Stem-cell Start-ups Seek to Crack the Mass-Production Problem

In the laboratory, induced pluripotent stem (iPS) cells can seem like magic: derived from...
Kytopen
September 29, 2021
Partners

Kytopen Raises $30M in Series A Funding, Led by Northpond Ventures, to Transform Non-Viral Delivery via the Flowfect Platform

Financing will accelerate momentum toward unlocking the linearity between discovery and...
Kytopen
September 28, 2021
Technology

Kytopen awarded NIH grant of up to $2M to unlock the power of engineered Natural Killer (NK) cells via Flowfect® platform

NIH/NIAID SBIR Fast Track grant accelerates the company’s commercial activities towards a non-viral...
Kytopen
June 15, 2021